论文部分内容阅读
目的探索恶性疟复合多价ＤＮＡ疫苗的可行性。方法把带有ＡＴＧ的接头与人工合成的恶性疟原虫复合多价抗原基因ＡＢ相连后，构建分别带有ＳＶ４０或ＲＳＶ启动子的真核表达载体ｐＳＶ２／ＡＢ及ｐＲＥＰ９／ＡＢ，重组表达质粒经肌肉注射免疫ＢＡＬＢ／ｃ小鼠后，检测其诱发特异性体液和细胞免疫应答水平及毒副作用。结果ｐＳＶ２／ＡＢ及ｐＲＥＰ９／ＡＢ免疫ＢＡＬＢ／ｃ小鼠后均诱发了一定水平的细胞及体液免疫应答，带ＲＳＶ启动子的ｐＲＥＰ９／ＡＢ免疫原性略强于带ＳＶ４０启动子的ｐＳＶ２／ＡＢ，ＤＮＡ免疫后未见明显的毒副作用。结论恶性疟复合多价ＤＮＡ疫苗可诱发特异的免疫应答，为疟疾ＤＮＡ疫苗的研究提供了一定的理论及实验依据
Objective To explore the feasibility of multivalent DNA vaccine against falciparum malaria. METHODS: The eukaryotic expression vectors pSV2 / AB and pREP9 / AB carrying the SV40 or RSV promoter were constructed by ligating the ATG-containing linker to the synthetically synthesized P. falciparum multivalent antigen gene AB. The recombinant plasmid BALB / c mice were injected with BALB / c mice to detect the level of specific humoral and cellular immune responses and toxicities and side effects. Results Both pSV2 / AB and pREP9 / AB immunized BALB / c mice induced some cellular and humoral immune responses. The immunogenicity of pREP9 / AB with RSV promoter was slightly stronger than that of pSV2 / AB with SV40 promoter. DNA immunization no obvious side effects. Conclusions The multi-valent DNA vaccine against falciparum malaria can induce specific immune response and provide some theoretical and experimental evidence for the research of malaria DNA vaccine